2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Glioblastoma
5
Lung Neoplasms
4
Head and Neck Neoplasms
4
Breast Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Glioma
3
Brain Neoplasms
3
Virus Diseases
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Neoplasms
2
Melanoma
2
Liver Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Pharyngeal Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Nose Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Interventions
Radiotherapy
122
Temozolomide
110
Carboplatin
53
Filgrastim
46
Vincristine
43
Etoposide
39
Cyclophosphamide
37
Chemotherapy, Adjuvant
37
Cisplatin
36
Carmustine
32
Irinotecan
27
Peripheral Blood Stem Cell Transplantation
25
Magnetic Resonance Spectroscopy
24
Lomustine
22
Thiotepa
21
Methotrexate
20
Granulocyte Colony-Stimulating Factor
18
Procarbazine
16
Bevacizumab
16
Surgical Procedures, Operative
15
O(6)-benzylguanine
14
etoposide phosphate
13
Drug Therapy
13
Topotecan
12
Paclitaxel
12
Ifosfamide
12
Thalidomide
11
Radiation
11
sargramostim
10
Specimen Handling
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
Oncolytic Virotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled